Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short term Debt (2018 - 2025)

Ani Pharmaceuticals' Short term Debt history spans 10 years, with the latest figure at $167000.0 for Q4 2025.

  • For Q4 2025, Short term Debt fell 98.18% year-over-year to $167000.0; the TTM value through Dec 2025 reached $167000.0, down 98.18%, while the annual FY2025 figure was $167000.0, 98.18% down from the prior year.
  • Short term Debt for Q4 2025 was $167000.0 at Ani Pharmaceuticals, up from $63000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $23.9 million in Q3 2023 and bottomed at $63000.0 in Q3 2025.
  • The 5-year median for Short term Debt is $850000.0 (2021), against an average of $7.1 million.
  • The largest annual shift saw Short term Debt soared 2716.35% in 2023 before it plummeted 98.18% in 2025.
  • A 5-year view of Short term Debt shows it stood at $850000.0 in 2021, then changed by 0.0% to $850000.0 in 2022, then changed by 0.0% to $850000.0 in 2023, then surged by 979.06% to $9.2 million in 2024, then tumbled by 98.18% to $167000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Short term Debt are $167000.0 (Q4 2025), $63000.0 (Q3 2025), and $13.2 million (Q2 2025).